Trulieve Boss Unfazed by DEA Involvement in Shift to Schedule III

The cannabis world is buzzing following the federal shift to Schedule III, and Trulieve’s Kim Rivers is leaning into what this actually looks like for the industry. While some folks are worried about the Drug Enforcement Administration taking on a "middleman" role in the supply chain to satisfy international treaties, Rivers isn't breaking a sweat. For the rest of us, this signal of progress means the days of the federal government ignoring the plant's benefits are finally coming to an end.

One of the biggest wins here for the everyday enthusiast is the potential for massive upgrades in product quality and variety. Since the plant is moving out of the most restrictive category, American researchers can finally get their hands on the same flower we see in dispensaries. Instead of relying on decades-old data, scientists can now study modern strains to figure out exactly how different terpene profiles and cannabinoids help with things like sleep or recovery. This means more consistent, lab-backed options for your next session.

On the business side, the removal of the 280E tax penalty is a total game-changer. For years, legal shops were taxed like illegal cartels, unable to deduct basic operating costs. With that burden lifted, these companies can finally reinvest in their facilities and staff. For you, that likely means better-designed dispensaries, more knowledgeable budtenders, and hopefully, more competitive pricing as the "cannabis tax" disappears.

Practical tip: As these federal changes roll out, keep an eye on your favorite local brands. You’ll likely see a wave of new formulations and specialized products hitting the shelves as clinical research ramps up. It’s a great time to ask your budtender about any new data-backed minor cannabinoids like CBN or THCV that might be showing up in new edibles or tinctures. We’re moving toward a smarter, more transparent era of cannabis, and that’s something every enthusiast can get behind.